Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Propranolol affects heart rate and renin levels in minoxidil-treated patients.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

MK-386 reduces sebum DHT levels.

This study reported that certain minoxidil conjugates, specifically those with spermine, methylenedianiline, and diaminofluorene, were able to induce differentiation in HL-60 acute myeloid leukemia cells without toxicity at a concentration of 10 μM.

This study suggests that combining the 5α-reductase inhibitor 4-MA with the antiandrogen Flutamide may improve prostate cancer therapy by additively inhibiting prostatic growth and androgen-sensitive functions in rats.

This study found that adding 7% chamomile extract to 5% minoxidil solution reduced cutaneous side effects like itching, scaling, and erythema in men with androgenic alopecia compared to using minoxidil alone.

This study observed that the compound EM-402 reduced 5α-reductase activity and sebaceous gland size in the flank organs and ears of hamsters, indicating potent localized anti-androgenic effects without systemic action.

The research examined Crown-X, a novel formulation containing Menstrual Stem Cells, and found that it promoted significant proliferation of human dermal papilla cells, suggesting its potential as a non-invasive treatment for male pattern baldness. Future clinical trials are necessary to confirm its efficacy.

This study found that supplementation with CL22209, a standardized Asparagus racemosus root extract, significantly reduced menopausal symptoms and improved hormonal regulation among early perimenopausal women, with notable improvements in vasomotor and menstrual symptoms compared to placebo, while being safe and well-tolerated over 120 days.

In this study, topical dehydroepiandrosterone (DHEA) doubled sebum production in women without systemic side effects, suggesting it may be a safe treatment for reduced sebum output related to menopause.

This article reviews the limited evidence on testosterone therapy for premenopausal women and notes a lack of long-term safety and effectiveness data for this population.

Sex steroids, especially progesterone, can slow down the growth of mouse melanoma cells.

This controlled study found that patients with androgenetic alopecia treated with a combination of subcutaneous adipose-derived mesenchymal stem cells and oral minoxidil showed significantly better hair growth outcomes than those treated with oral minoxidil alone, with improvements ranging from 25-40% versus 5-10% over six months.

This study found that Soluplus and L-ascorbyl 2,6-dipalmitate nanoparticles may improve minoxidil's skin permeability through stable hydrophobic interactions, enhancing its potential for targeted skin application.

Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.

This research suggests that fluoxymesterone, an anabolic steroid, may inhibit a key enzyme, potentially contributing to cardiovascular issues by affecting cortisol's activation of mineralocorticoid receptors.

In this randomized clinical trial, minoxidil at 5 mg was not found to be superior to 2.5 mg for treating male androgenetic alopecia over 24 weeks, though the higher dose more frequently caused side effects like pre-tibial edema and dizziness.

This study developed and validated a sensitive HPLC–MS/MS method for detecting seven prohibited substances in cosmetic products.

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

In this study, researchers examined a new propylene glycol-free 5% minoxidil lotion for 6 months among individuals with androgenic alopecia and found it demonstrated good clinical efficacy, with 74% showing a positive response, and very high cosmetic acceptability and tolerability, comparable to traditional formulations.

This abstract describes monilethrix, an autosomal dominant genodermatosis with symptoms like hair fragility and keratosis pilaris, and does not report new experimental results.

This review concluded that low-dose oral minoxidil is an effective and well-tolerated treatment for male androgenetic alopecia, with significant hair density improvements and manageable side effects.